

Role of Surgery in Cancer Prostate

Dr. Ganesh Gopalakrishnan

Professor & Head
Department of Urology
Christian Medical college
Vellore





Some entirely unrelated history of medicine...

The roots are in urology...

Walker, Anthony., Physick, 1763



Panderen, Egbert van, 1581-1637

PROSTATE CANCER Highest in Incidence and Second in Cause of Death from Cancer in American Males Incidence Cause of Death Melanoma of Skin 4% **Esophagus** Oral Cavity & Pharynx 3% 31% Lung & Bronchus Lung & Bronchus 15% **Pancreas** Pancreas 2% 3% Kidney Colon & Rectum 10% 4% Liver 9% Colon & Rectum Kidney 4% Prostate 29% 9% Prostate Urinary Bladder 7% Urinary Bladder Leukemia 3% Leukemia Non-Hodgkin's Lymphoma 4% Non-Hodgkin's Lymphoma All Sites 766.860 289.550 All Sites 219,000 New Cases 27,000 Deaths 2007 Estimates

Bangalore : 2.1 per 100,000 cases

Mumbai: 3.5


Delhi : 3.6 National cancer registry

Chennai: 4.0

Autopsy data

- 30% of men older than 50 years
- 70% of men older than 80 years
- Life time risk of developing clinically detected prostate cancer: 16%.

Cancer Incidence Rates* for Men, 1975-2003



PSA era

1960 – Albin et al, novel seminal protein

1971 – Hara et al, protein unique to seminal fluid

1979 - Wang et al, PSA

1985 – post coital investigation of rape victim.

1987 – Stamey et al, first clinical study on utility of PSA in prostate cancer.

Jewett Staging













TNM Staging

T1: Microscopic tumor confined to prostate and undetectable by a digital rectal exam (DRE) or ultrasound

T1a: found in 5% or less of prostate tissue sample

T1b: found in more than 5% of a prostate tissue sample

T1c: identified by needle biopsy as a follow-up to screening that detected elevated PSA results

T2: confined to prostate and can be detected by DRE or ultrasound

T2a: involves less than half of one lobe

T2b: involves more than half of one lobe

T2c: involves both lobes of the prostate

T3: Spread to surrounding tissues or to the seminal vesicles

T3a: Spread on only one side

T3b: Spread on both sides


T3c: Spread to one or both of the seminal tubes


T4: Still within the pelvic region but may have spread to organs near the prostate

T4a: Spread to the bladder neck, the external sphincter, and/or the rectum

T4b: May affect the levator muscles / pelvic wall.

Prostate Cancer Trends Influence of PSA Assay






Treatment options for prostate cancer

- Observation alone.
- Radical prostatectomy.
- Radiation therapy.
- Hormonal treatment.

Cumulative incidence of distant metastasis and of death from any cause







Figure 2. Cumulative Incidence of Distant Metastasis (Panel A) and of Death from Any Cause (Panel B).



Localized Prostate cancer

- Confined to the prostate gland
- T1 or T2 lesion.
- Radical prostatectomy gold standard?

Factors to be considered for surgical management

- Patient selection
- Risk stratification
- Pre-operative counseling
- Surgical options
- Post-operative complications

Radical prostatectomy Patient selection

- Less than 60 yrs
- Good general health
- Life expectancy >10yrs
- No life threatening ancillary disease
- Removal of entire prostate and seminal vesicle
- Pelvic lymphadenectomy for staging
- Preservation of distal sphincter
- Preservation of cavernosal nerves to prevent impotence
- Clinically localized T1, T2 & T3

Risk stratification for clinically localized prostate cancer

Low risk

Diagnostic PSA < 10.0 ng/mL and Highest biopsy Gleason score < 6 and Clinical stage T1c or T2a

Intermediate risk

Diagnostic PSA > 10 but < 20 ng/mL or Highest biopsy Gleason score = 7 or Clinical stage T2b

High risk

Diagnostic PSA > 20 ng/mL *or*Highest biopsy Gleason score > 8 *or*Clinical stage T2c/T3
PSA = prostate-specific antigen

D'Amico et al

Rationale for surgical treatment

- Only 9-10% of cancers detected by PSA were indolent.
- 23% of T1c cancers and 40% of T2 tumours
 had advanced pathologic features
- High likelihood of cure for tumours detected early.

Surgical options


- Radical retropubic prostatectomy
- Radical perineal prostatectomy
- Laparoscopic radical prostatectomy
- Robotic prostatectomy


Open Surgical Approach


➤ 3-4 hours, general anesthesia.


➤ Incision: 8 cm
Begins just below
navel and extends to
pubic bone.


Remaining Urethra is sewn to bladder neck over a catheter.







































Complications

Bleeding
Incontinence
Erectile dysfunction

Laparoscopic Radical Prostatectomy

- Eliminates the need for a incision by using a telescopic instruments called a laparoscopes.
- Small camera attached to the laparoscope allows the surgeon to view inside the abdomen.
- More rapid recovery
- Unclear if any benefit for cancer cancer control, urinary or sexual function.



The Da Vinci system: Robotic Prostatectomy

- Surgeon operates from a console with a 3-D screen.
- Grasp controls to manipulate surgical tools within the patient.
- Robotic arms translate finger, hand, and wrist movements.
- Shortens learning curve of surgeons
- ▶ Very High-Precision
- ➤ Cost, Benefit unclear



Comparison of all three types of Radical prostatectomies

TABLE I. Odds ratios (ORs) for key outcomes*

Variables	Open Radical Prostatectomy (reference values)	Laparoscopic Radical Prostatectomy ¹⁹ (OR)	Robotic Prostatectomy ¹⁷ (OR)
Operating room times	163 min	1.51 [†]	0.91‡
EBL	910 mL	0.42 [†]	0.10 [†]
Positive margins	23%	1	1
Complications	15%	0.67 [†]	0.33 ^{†‡}
Catheter time	15.8 days	0.50 [†]	0.44 [†]
Hospital stay >24 hr	100%	0.35 [†]	0.07 ^{†‡}
Postoperative pain score scale (0–10)	7	0.45 [†]	0.45 [†]
Median time to continence	160 days	1	0.28 ^{†‡}
Median time to erection	440 days	NA	0.4 [†]
Median time to intercourse	>700 days	NA	0.5 [†]
Detectable PSA	15%	1	0.5

EBL = estimated blood loss; NA = not available, because most patients undergoing laparoscopic radical prostatectomy were not sexually active at baseline; PSA = prostate-specific antigen.


Adapted from BJU Int17 and J Urol.19


^{*} The reference values were those from conventional radical prostatectomy. OR was the ratio of the observed to the reference value.

 $^{^{\}dagger}$ P < 0.05 vs robotic prostatectomy.

 $^{^{\}dagger}$ P < 0.05 vs laparoscopic radical prostatectomy.

Trifecta nomogram





Probability of BCR (biochemical recurrence) with time

Probability of continence recovery after RP

Treatment metastatic disease

- Mainly palliative
- Eliminates symptoms in most symptomatic patients
- Prolongs time to clinical progression
- Prolongs survival

Results of Androgen Removal

Bilateral orchidectomy

- Gold standard
- Done under local anesthesia
- Rapid lowering of serum testosterone level
- Side effects less
- Cost effective
- Testicular prosthesis –cosmetic result

Side effects

- > Impotence
- Loss of sexual desire (libido)
- Hot flashes
- Weight gain
- Fatigue
- Loss of muscle and bone mass

Locally advanced

- TURP
- PCN
- DJ STENT
- In conjunction with HRPC status

Bony metastases

Prophylactic surgical fixation - indications

- lytic lesion
- 2. in a weight bearing bone
- 3. equal to or more than 50% of the C.S diameter.
- 4. >2.5 cms in length.
- 5. impending cord compression.
- 6. in the region that had received RT before.

Is cure necessary in those in whom it may be possible, and is cure possible in those in whom it is necessary?

Whitmore

Prostate Cancer

A pound of prevention, ounce of cure

